Xerostomia Clinical Trial
Official title:
Comparison of Two Photobiomodulation Protocols for the Oral Mucositis and Xerostomia Prevention in Irradiated Head and Neck Cancer Patients: a Randomized, Multicenter, Single-blind Controlled Clinical Trial
Head and neck cancer (HNC) are among the most frequent malignancies in the world. The main treatment modalities for HNC are surgical excision, radiotherapy (RT), and chemotherapy (CT). Severe oral sequelae such as oral mucositis (OM), dysgeusia, opportunistic infections, trismus, and xerostomia/hyposalivation can affect HNC patients due to oncological treatment with RT and QT. Photobiomodulation therapy (PBMT) with an intraoral low-power laser has been studied as an excellent tool in the management of OM and xerostomia and thus improves the tolerability of RT in the head and neck region. The aim of this multicenter, randomized, single-blind clinical trial is to compare the effects of two photobiomodulation protocols (intraoral application low-level laser and defocused extraoral application of high-power laser) in the management of oral mucositis (OM) and xerostomia in head and neck cancer patients undergoing radiotherapy (RT). It is expected defocused extraoral high-power photobiomodulation shows results as good as intraoral photobiomodulation on the management of oral mucositis.
Radiotherapy (RT) and chemotherapy-induced oral side effects, as oral mucositis, and xerostomia are extremely challenging for professionals in the supportive care for head and neck squamous cell carcinoma (HNSCC) patients. There is a substantial evidence about the benefits of photobiomodulation in the management of these oral side effects, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief by intraoral low-level lasers. However, new parameters as extraoral applications by defocused high-power lasers have been investigated to improve the OM outcomes, the patients' complaints, and the experience in the clinical assistance by professionals. Thus, 132 H&N cancer patients will be, globally and simultaneously, randomized according to clinical stage of head and neck cancer, type of treatment (isolated RT or RT and QT), type of RT (RTC3D or IMRT) and center involved (A.C. Camargo Cancer Center or State of São Paulo Cancer Institute or Porto Alegre Clinics Hospital). The randomized patients can be allocated into two groups: Group I: intraoral photobiomodulation with low level laser therapy (660nm, 100 mW, 10 J/cm2, 3 s/point) and Group II: extraoral photobiomodulation with high level laser therapy (810 + 980 nm, 1000 mW, 6.11 J/cm2, 30 s/point). PBMT will be performed daily, 5 times per week during the radiotherapy or until wound healing of OM lesions by a trained professional. Oral mucositis, pain, xerostomia, dysphagia, dysgeusia, oral functions, labial hydration and radiodermatitis will be evaluated daily. Salivary flow and trismus will be assessed weekly, and two questionaries (OHIP-14 and Vanderbilt) will be assessed on the first day of RT, on the middle of RT regimen, on the final of RT regimen and three months later RT sessions. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05342272 -
Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction
|
Phase 3 | |
Completed |
NCT03302676 -
The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors
|
N/A | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Completed |
NCT01272570 -
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
|
N/A | |
Completed |
NCT00656513 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00911768 -
Effect of Korean Red Ginseng (KRG) on Dry Mouth
|
Phase 4 | |
Completed |
NCT00332618 -
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
|
Phase 2 | |
Completed |
NCT03494985 -
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
|
N/A | |
Completed |
NCT05058430 -
SaliPen Human Factors Study for OTC Labeling
|
N/A | |
Recruiting |
NCT02705937 -
Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.
|
N/A | |
Completed |
NCT05247008 -
Effectiveness of Thyme Honey in Management of Xerostomia in ESRD
|
N/A | |
Recruiting |
NCT03632096 -
Photobiomodulation in Salivary Production of Patients With Xerostomy
|
Phase 2 | |
Not yet recruiting |
NCT04323384 -
The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing
|
N/A | |
Not yet recruiting |
NCT03530735 -
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
|
N/A | |
Active, not recruiting |
NCT03176368 -
Coconut Oil: Managing Radiation-Induced Xerostomia
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Completed |
NCT02682199 -
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
|
||
Withdrawn |
NCT01960101 -
Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
|
N/A | |
Completed |
NCT02317172 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases
|
N/A |